An FDA advisory panel voted this week to add six peptides to the drug compounding list, including compounds like kisspeptin and TB-500. The panel turned down emideltide. HIMS stock rose as shares jumped overnight after the committee backed four peptides. Bachem shares held steady after the vote. A recent study indicated peptides may assist with combating antibiotic-resistant bacteria. Meanwhile, Kennedy called for expanded access to controversial peptides, calling for slackened rules. The vote reflects a broader shift in how policymakers view custom-mixed peptide therapies, which have drawn increasing interest from users seeking alternatives to traditional drugs. Researchers say peptide treatments could reshape approaches to difficult infections, though concerns about safety persist. The committee's endorsement of six peptides opens the door for more expanded prescribing, even as watchdogs warn of short-term evidence. Industry analysts note that peptide-focused companies may see heightened investor attention following the panel's decision. The rejection of emideltide, meanwhile, underscores the FDA's cautious stance on particular peptide candidates.